Scancell Share Discussion Threads

[chilltime] 14/11/2024 17:57

Adding facts to posts.

Question posted

Did Lindy/Scancell ever say Scib1 trial would end early/not go to 43.

Answer given Yes it was in an interview by Lindy

Interview below, comment a couple of minutes in

[chilltime] 14/11/2024 17:01

Interesting day🤔

It will open up 5.6% tomorrow in theory due to a small UT trade skewing the closing real mid price 15-15.75

But then 2 trades 50k at the top end of the offer near close, caused the UT spread to be 15.25-16. So it could open at 15.625 (+9%)

Odd action, we’ll see tomorrow, Scib data 🤷‍a94;️

Thanks, Lindy run rate required hit, just 20 more like that please👍

[inanaco] 14/11/2024 15:13

Ok lindy has confirmed ... that my thought process was a possibility

a Pd-1/vegf antibody could upregulate Moditope (increase the flags seen by moditope activated t cells)

But as Lindy says they have to get it registered first

so again Synergy is in play as the market develops for this form of Checkpoint

[marcusl2] 14/11/2024 14:54

Phil L’Huillier, incoming Chief Executive Officer, Scancell, added: “We are on the verge of a revolution in cancer therapy, driven by greater understanding of the human adaptive immune system. I am delighted to join Scancell at such an exciting juncture, with the company’s complementary cancer vaccine platforms, ImmunoBody® and Moditope®, showing incredible potential in the clinic.

[inanaco] 14/11/2024 14:48

we keep sayings its a land grab patent ..............moditope



Citrullinated fibrinogen-SAAs complex causes vascular metastagenesis




Primary tumor cells metastasize to a distant preferred organ. However, the most decisive host factors that determine the precise locations of metastases in cancer patients remain unknown. We have demonstrated that post-translational citrullination of fibrinogen creates a metastatic niche in the vulnerable spots. Pulmonary endothelial cells mediate the citrullination of fibrinogen, changing its conformation, surface charge, and binding properties with serum amyloid A proteins (SAAs), to make it a host tissue-derived metastatic pathogen. The human-specific SAAs-citrullinated fibrinogen (CitFbg) complex recruits cancer cells to form a protein-metastatic cell aggregation in humanized SAA cluster mice. Furthermore, a CitFbg peptide works as a competitive inhibitor to block the homing of metastatic cells into the SAAs-CitFbg sites. The potential metastatic sites in the lungs of patients are clearly visualized by our specific antibody for CitFbg. Thus, CitFbg deposition displays metastatic risks for cancer patients, and the citrullinated peptide is a new type of metastasis inhibitor.

[inanaco] 14/11/2024 14:16

Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy

and you do a little bit of research and ....


Furthermore, cellular stress and autophagy, e.g., during chronic inflammation and tumor progression, can cause citrullination of vimentin. This creates immunogenic epitopes that can give rise to autoantibodies or can be helpful in antitumor responses43,44. Regardless of possible posttranslational modifications (PTMs) in extracellular vimentin in vitro or in vivo, our data demonstrate functional effects of both application and (antibody-based) targeting of unmodified vimentin.

We here demonstrate that extracellular vimentin specifically interacts with and activates VEGFR2 and modulates VEGF signaling, increases VEGF receptor expression, and shares functional modes of action with VEGF. VEGF induces endothelial permeability, a.o. through direct interaction between VEGFR2 and VE-cadherin, resulting in transactivation of VE-cadherin and subsequent activation of β-catenin and internalization of VE-cadherin45. Our finding that extracellular vimentin can directly activate VEGFR2 places vimentin as an additional player in this process. Interestingly, extracellular vimentin has been reported to induce phosphorylation of β-catenin in colorectal cancer cells accompanied by activation of the Wnt pathway, although no cellular receptor was conclusively identified15.

Other putative cell surface receptors that interact with vimentin, which may play relevant roles in tumor angiogenesis and immune suppression, have been identified. These interactions may enhance or synergize with the here reported binding of vimentin to VEGFR2 and its consequent effects. For example, insulin-like growth factor 1 receptor (IGF1R), extensively involved in tumor angiogenesis46 was shown to be activated by the C-terminus of vimentin, thereby promoting axonal growth47, a process that shows resemblance to blood vessel formation. In addition, the hyaluronic acid-binding domain of CD44, an EC- and leukocyte adhesion receptor48, was demonstrated to interact with the N-terminus of vimentin49. Together with the observation that vimentin can bind P-selectin, also involved in EC-leukocyte interactions50, these findings indeed support a multifaceted modulatory role for extracellular vimentin in tumor angiogenesis and immunity.

In all, our data demonstrate that vimentin, like VEGF, (i) reduces VE-cadherin expression, cell-cell interactions and vascular integrity, (ii) supports tumor angiogenesis, and (iii) hampers antitumor immunity. It is therefore considered that extracellular vimentin is a master regulator of EC anergy, the phenomenon of tumor endothelial non-adhesiveness and unresponsiveness to inflammatory cytokines3. EC anergy was recently assigned the role of vascular immune checkpoint5. As such, inhibitors of angiogenesis can overcome EC anergy and potentiate immunotherapy, a concept that is currently in full development in the clinic5. Also, vimentin potentiates the expression of endothelial PD-L1, leading to immune exhaustion, and vaccination against vimentin was demonstrated to suppress tumor endothelial PD-L1 expression.

[inanaco] 14/11/2024 13:41

I have always said because industry is concentrating on the TME ....

it plays into scancells domain ... we never lose competitive advantage

[inanaco] 14/11/2024 13:39

another point ...

they probably act very similar to PD-1 with an increase PFS role ...

Ctl-4 is the blast at the start of treatment its not an ongoing treatment this is when you need the pd-1

so you could still potential blast the initial potency of the vaccine with Ctl-4

which also up regulates PD-1 ... with the Vegf acting against Vascular growth within the tumour

this has an interesting effect .............. it starves the cancer

which UP regulates Citrullination which is a response to starvation

[inanaco] 14/11/2024 13:32

couple of points about this potential new approach to checkpoints ...

for Scancell it would have to do a deal because the Ci are unapproved thus the trial sponsor would have to pay for all drugs ..

however multiple players are now in the game ... and they need to get an edge over each other

synergy of vaccines ..

comes into play again

Biontech could use its own vaccines ...

what would Merck use ?

[inanaco] 14/11/2024 13:27

Merck, the maker of the drug they’re trying to beat, is entering the PD-1/VEGF space by handing down $588 million upfront to get the exclusive global license to a Phase 1 asset from LaNova Medicines.

The New Jersey pharma giant could dish out up to another $2.7 billion in biobucks to Shanghai-based LaNova. Last month, the five-year-old startup said it started a Phase 1 in China for the experimental medicine, dubbed LM-299. It also said it planned to file an IND in the US in the second half of the year after securing $42 million in a Series C1.

Merck has been one of the most acquisitive pharmas in recent years in an attempt to shore up the looming patent cliff for the world’s best-selling medicine, the immunotherapy Keytruda. It’s bought three companies this year — EyeBio, Abceutics and Harpoon Therapeutics — and paid $700 million for a bispecific antibody from Curon.

[bermudashorts] 14/11/2024 13:14

marcus - a vast improvement, as was the presentation of the last annual report

[chilltime] 14/11/2024 13:11

Thanks Marcus

A nice new look ready for the shouting, avengers assembled.

[inanaco] 14/11/2024 12:57

i would also point out the deals we have in place are Dollar based

the £ is still declining against the Dollar ....

thus the transactions that may be up coming are going up in value in sterling terms

likewise the Predicted SCIB1 $ pricing is moving in our favour

which in turn makes scancell more attractive !!

[inanaco] 14/11/2024 12:48

you live in a hyperbaric chamber Loz called Utopia

the good news we cannot hear you !

and Buy Buy Buy ... is not affected

[marcusl2] 14/11/2024 12:45

JB1

Scancell's Website has been Spruced Up

[the real lozan] 14/11/2024 12:41

There CAN be 'NO question' as to inane'n'co's CONtribution to the *medical science*
especially, in the 'Psychiatric' branch of 'medical research'

[inanaco] 14/11/2024 12:34

well you clarified that after the "error" was pointed out ...

this for you was about adapting your lying after the event, having being caught

only 1 train movement .... was described ... away from the AGM

squirming ...

at the time it was hilarious

anyway hope the wood is drying nicely ...

[the real lozan] 14/11/2024 12:27

As stated at the time
I arrived at East Midlands a day ahead of said AGM
Took the train to Nottingham in order to visit/stay with friends
Attended the AGM following day the flew back to France from East Midlands
.
the problem IS lying about vents .... OR simply getting things WRONG... again
.

As WE ALL know of YOUR 'tactic' of recovering other folks posts from years back... when it suits YOU
perhaps there is some 'reason' YOU refrain from bringing up my original AGM visit post ???
Might that be = It would clearly show ===YOU are , again,,, A LYING ???

[inanaco] 14/11/2024 12:13

if i recall you attended an AGM loz

you arrived at East Midlands airport then caught a train to Nottingham to attend the AGM

which was held at East Midlands Airport

that is the problem with lying without the research

[marcusl2] 14/11/2024 12:08

Sanofi (Euronext: SAN) has announced that the UK's health technology assessor will conduct a new review of its Sarclisa (isatuximab) combo therapy for relapsed or refractory multiple myeloma.

The review will address treatment at fourth-line in patients whose cancer has advanced after treatment with lenalidomide and a proteasome inhibitor.

The reappraisal follows Sanofi’s successful appeal of an unfavorable draft issued by the National Institute for Health and Care Excellence (NICE) in June, which judged that Isa-Pd would not meet cost-effectiveness criteria even at a hypothetical zero price point.

[the real lozan] 14/11/2024 12:05

"Loz is waiting for"
For YOU to admit that YOU got on the WRONG train
Then ...Blamed the traindriver for YOUR mistake
Waiting for YOU to 'admit' any error... is sure to be boring enough

[inanaco] 14/11/2024 12:05

I refer back to my post the other day



inanaco - 13 Nov 2024 - 17:28:44 - 13936 of 14058 Scancell - Pot of Gold or POS? - SCLP
some should seriously consider what is going on.......

a few months ago the market was being sucked dry of shares which then stalled slightly as the "feeder" over supplied, and traders being smart started to bring the share price down however Mr Dyson was not finished and still kept buying but at a slower rate because he to was as smart as the traders now in "nibble mode" ....

13-Nov-24 16:38:16 14.25 100,000 Buy* 13.50 14.50 14.25k

what fed that trade was an increase in the bid ....indicating a share shortage

you have no idea what will happen when news breaks or how much scancell will spread the gossip ...

however look at the number of "presentations" that went on through out the year

sparking a serious amount of interest ... and "appointments" including the Blind review Committee

I have no idea what goes on in peoples heads it baffles me from the worse Justin Welby .... what was he thinking ....

to the Labour Parties Ni increase ... with no thought given

But Here its different ......

its all laid out in front of you ... !

yet people sell !!

or are scared to buy ............... !!!!!

like i said if i am wrong a disaster for scancell .....

But why are so many joining Scancell including the Blind review panel

the question then should be ...............

why are all these extremely smart people joining scancell ....